NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors

Chemotherapy

Volumn 55, Issue 5, 2009, Pages 381-385

  Burnik, Ferda Sevimli ^a   Yalçin, Şuayib ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Neuroendocrine tumor; NFKB1 gene; Nuclear factor B; Promoter polymorphism

Indexed keywords

AGAROSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B[1-94]; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG;

ADULT; AGAR GEL ELECTROPHORESIS; APPENDIX TUMOR; ARTICLE; BLADDER CANCER; CASE CONTROL STUDY; CECUM TUMOR; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROL GROUP; CONTROLLED STUDY; DUODENUM TUMOR; FEMALE; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; HUMAN TISSUE; ILEUM TUMOR; MALE; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECTUM TUMOR; STOMACH TUMOR;

ADULT; AGED; CARCINOID TUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE FREQUENCY; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NF-KAPPA B P50 SUBUNIT; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 70049083278     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000237744     Document Type: Article

References (37)

1. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr: Constitutive activation of NF-κB during progression of breast cancer to hormone independent growth. Mol Cell Biol 1997;7:3629-3639. (Pubitemid 27281838)
2. Alvarez FN, Carlson LM, Lindner I, Lee KP: 6,7-dihydroxy-3,4- dihydroisoquinoline: a novel inhibitor of nuclear factor-kappaB and in vitro invasion in murine mammary cancer cells. Chemotherapy 2009;55:175-182.
3. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, et al: Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 1996;15:4682-4690. (Pubitemid 26294586)
4. Wang CY, Mayo MW, Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996;274:784-787.
5. Notarbartolo M, Lo Cicero S, Meli M, et al: Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possible relationship to the effects on inhibitor of apoptosis protein levels. Chemotherapy 2005;51:272-279. (Pubitemid 41207049)
6. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;274:787-789.
7. Shishodia S, Aggarwal BB: Nuclear factor-kappa B activation: a question of life and death. J Biochem Mol Biol 2002;35:28-40. (Pubitemid 34363111)
8. Rayet B, Gelinas C: Aberrant Rel/NFκB genes and activity in human cancer. Oncogene 1999;18:6938-6947.
9. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V: The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-149. (Pubitemid 24045827)
10. Mukhopadhyay T, Roth JA, Maxwell SA: Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999-1003.
11. Liptay S, Schmid RM, Perkins ND, Meltzer P, Altherr MR, McPherson JD, et al: Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2. Genomics 1992;13:287-292.
12. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al: Constitutive activation of NF-κB-RelA is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-2969. (Pubitemid 28022832)
13. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, et al: Expression of a dominant negative mutant inhibitor of NF-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res 1999;59:3468-3474. (Pubitemid 29334510)
14. Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, Bours V: Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999;18:2567-2577. (Pubitemid 29216679)
15. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-127. (Pubitemid 29045184)
16. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, et al: An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999;161:674-679.
17. Devalaraja MN, Wang DZ, Ballard DW, Richmond A: Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res 1999;59:1372-1377.
18. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, et al: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF kappaB p65 protein expression. Oncogene 1997;15:1987-1994. (Pubitemid 27480687)
19. Héron E, Deloukas PP, Van Loon AP: The complete exon-intron structure of the 156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription factors NF-κB and IκB-g: implications for NF-κB mediated signal transduction. Genomics 1995;30:493-505. (Pubitemid 26041490)
20. Mathew S, Murty VS, Dalla-Favera R, Chaganti RS: Chromosomal localization of genes encoding the transcription factors, c-Rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene 1993;8:191-193. (Pubitemid 23047246)
21. Karban AS, Okazaki T, Punhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45. (Pubitemid 38072133)
22. Borm ME, van Bodegraven AA, Mulder CJ, Kral G, Bouma G: A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005;32:401-405.
23. Orozco G, Sanchez E, Collado MD, López-Nevot MA, Paco L, García A, et al: Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2005;65:183-186. (Pubitemid 40342450)
24. Rueda B, Nunez C, Lopez-Nevot MA, Paz Ruiz M, Urcelay E, De la Concha EG, Martin J: Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease. Scand J Gastroenterol 2006;41:420-423. (Pubitemid 43675407)
25. Curran JE, Weinstein SR, Griffiths LR: Polymorphic variants of NFKB1 and its inhibitory protein NFKB1A and their involvement in sporadic breast cancer. Cancer Lett 2002;188:103-107.
26. Kim TH, Stone MA, Rahman P, Yoo DH, Park YW, Payne U, et al: Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. J Rheumatol 2005;32:1907-1910. (Pubitemid 41429020)
27. Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, et al: Swedish Low-Risk Colorectal Cancer Study Group. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 2007;42:1332-1338.
28. Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W: Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007;45:423-430. (Pubitemid 47243938)
29. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17. (Pubitemid 29036378)
30. Baldwin AS Jr: Series introduction: the transcription factor NF-κB and human disease. J Clin Invest 2001;107:3-6.
31. Yamamoto Y, Gaynor, RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142. (Pubitemid 32096826)
32. Roncalli M, Springall DR, Varndell IM, Gaitonde VV, Hamid Q, Ibrahim NB, et al: Oncoprotein immunoreactivity in human endocrine tumours. J Pathol 1991;163:117-127.
33. Wang DG, Johnston CF, Buchanan KD: Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implication for pathogenesis. Cancer 1997;80:668-675.
34. Chaudhry A, Papanicolau V, Oberg K, Heldin CH, Funa K: Expression of platelet derived growth factor and its receptors in neuroendocrine tumours of the digestive system. Cancer Res 1992;52:1006-1012.
35. Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman H: Presence of IGF-I in human midgut carcinoid tumours: an autocrine regulator of carcinoid tumour growth? Int J Cancer 1992;51:195-203.
36. Öberg K: Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001;47:40-53. (Pubitemid 32238643)
37. La Rosa S, Chiaravalli AM, Capella C, Uccella S, Sessa F: Immunohistochemical localization of acidic fibroblast growth factor in normal human enterochromaffin cells and related gastrointestinal tumours. Virchows Arch 1997;430:117-124. (Pubitemid 27121110)